Axonicsの空売り状況は、投資家がAxonicsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Axonics (NASDAQ:AXNX) 株価情報, 空売り情報

Axonics

Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is predominantly used to treat patients with overactive bladder, fecal incontinence, and urinary retention. Geographically, the company generates majority of its revenue from United States and rest from International markets.

Axonics Modulation Tech

Axonics Inc

Lantronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRX#NASDAQ">LTRX</a>) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.09 by 33.33 percent. This is a 14.29 percent decrease over earnings of $0.07 per share from the same period last year. The company reported quarterly sales of $34.42 million which missed the analyst consensus estimate of $36.31 million by 5.20 percent. This is a 4.21 percent increase over sales of $33.03 million the same period last year.

Earnings

Earnings Misses

News

LTRX

Lantronix Q1 Adj $0.06 Misses $0.09 Estimate, Sales $34.42M Miss $36.31M Estimate

Fossil Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOSL#NASDAQ">FOSL</a>) lowers FY2024 sales outlook from $1.20 billion to $1.10 billion.

Guidance

FOSL

Fossil Group Lowers FY2024 Sales Guidance from $1.20B to $1.10B

Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.75) by 5.33 percent.

Earnings Beats

RCKT

Rocket Pharmaceuticals Q3 2024 GAAP EPS $(0.71) Beats $(0.75) Estimate

CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) affirms FY2024 sales outlook from $225.00 million-235.00 million to $225.00 million-235.00 million.

CYRX

CryoPort Affirms FY2024 Sales Guidance to $225.00M-235.00M  VS Est.229.73M

NV5 Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVEE#NASDAQ">NVEE</a>) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.41 by 7.32 percent. This is a 22.22 percent increase over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $250.885 million which missed the analyst consensus estimate of $252.108 million by 0.49 percent. This is a 4.85 percent increase over sales of $239.287 million the same period last year.

NVEE

NV5 Global Q3 2024 Adj. EPS $0.44 Beats $0.41 Estimate, Sales $250.885M Miss $252.108M Estimate

FRLA

Fortune Rise Acquisition Extends To Complete Business Combination From Nov. 5 To Dec. 5

WIIM

PRPH

ProPhase Labs shares are trading lower after the company announced its intention to sell shares through a public offering.

Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.02 by 200 percent. The company reported quarterly sales of $213.300 million which beat the analyst consensus estimate of $210.729 million by 1.22 percent. This is a 11.15 percent increase over sales of $191.900 million the same period last year.

MYGN

Myriad Genetics Q3 2024 Adj. EPS $0.06 Beats $0.02 Estimate, Sales $213.300M Beat $210.729M Estimate

Buybacks

DVAX

Dynavax Launches $200M Share Buyback Program With Board Approval; Repurchases Expected To Be Completed Within One Year

ON24 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTF#NYSE">ONTF</a>) raises FY2024 Adj EPS guidance from $0.05-0.08 to $0.08-0.10 vs $0.07 analyst estimate. Raises FY2024 sales outlook from $145.00 million-147.80 million to $146.80 million-147.80 million vs $146.33 million estimate.

ONTF

ON24 Raises FY2024 Adj EPS Guidance from $0.05-0.08 to $0.08-0.10 vs $0.07 Est; Raises FY2024 Sales Guidance from $145.00M-147.80M to $146.80M-147.80M vs $146.33M Est

Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) affirms FY2024 sales outlook from $1.40 billion-1.60 billion to $1.40 billion-1.60 billion.

Bloom Energy Affirms FY2024 Sales Guidance to $1.40B-1.60B  VS Est.1.47B

Phunware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.26) by 3.85 percent. This is a 90 percent increase over losses of $(2.50) per share from the same period last year. The company reported quarterly sales of $665.00 thousand which missed the analyst consensus estimate of $1.31 million by 49.24 percent. This is a 46.88 percent decrease over sales of $1.25 million the same period last year.

PHUN

Phunware Q3 EPS $(0.25) Beats $(0.26) Estimate, Sales $665.00K Miss $1.31M Estimate

Apartment Inv &amp; Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIV#NYSE">AIV</a>) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.11) by 45.45 percent. This is a 700 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $53.16 million which beat the analyst consensus estimate of $52.60 million by 1.06 percent. This is a 11.44 percent increase over sales of $47.70 million the same period last year.

Apartment Inv & Mgmt Q3 EPS $(0.16) Misses $(0.11) Estimate, Sales $53.16M Beat $52.60M Estimate

New facility will enable testing of liquid hydrogen (LH2), liquid oxygen (LOX) and liquid methane (LCH4)

Graham To Construct Cryogenic Propellant Testing Facility

ON24 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTF#NYSE">ONTF</a>) is looking for Q4 Adj EPS of $0.01-0.02 vs $0.01 analyst estimate. sees sales of $35.400 million-36.400 million vs $35.87 million estimate.

ON24 Sees Q4 Adj EPS $0.01-0.02 vs $0.01 Est; Sees Sales $35.400M-36.400M vs $35.87M Est

MRVI

Maravai LifeSciences To Acquire Officinae Bio's DNA And RNA Business, Enhancing Nucleic Acid Research Capabilities; Acquisition To Boost Maravai's mRNA Manufacturing Through TriLink BioTechnologies

Lionsgate Studios (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LION#NASDAQ">LION</a>) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.06) by 550 percent. This is a 750 percent decrease over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $823.70 million which beat the analyst consensus estimate of $748.00 million by 10.12 percent.

LION

Lionsgate Studios Q2 2025 GAAP EPS $(0.39) Misses $(0.06) Estimate, Sales $823.70M Beat $748.00M Estimate

Lantronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRX#NASDAQ">LTRX</a>) is looking for Q2 Adj EPS of $0.01-0.05 vs $0.10 analyst estimate. sees sales of $29.000 million-33.000 million vs $38.60 million estimate.

Lantronix Sees Q2 Adj EPS $0.01-0.05 vs $0.10 Est; Sees Sales $29.000M-33.000M vs $38.60M Est

FIGS

FIGS shares are trading lower after the company reported worse-than-expected Q3 revenue results and cut its FY24 revenue guidance.

BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) is looking for Q4 Adj EPS of $0.47-0.52 vs $0.51 analyst estimate. seessales of $167.000 million-169.000 million vs $168.08 million estimate.

BlackLine Sees Q4 Adj EPS $0.47-0.52 vs $0.51 Est; Sees Sales $167.000M-169.000M vs $168.08M Est

Top Merger Stocks Held By Fund Managers, Mid-Q3 2024

Tracking George Soros's 13F Portfolio - Q2 2024 Update

Axonics gains after win in trial in patent dispute with Medtronic

Piper Sandler analyst Adam Maeder maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report) today and set a price target...

Piper Sandler Keeps Their Hold Rating on Axonics Modulation Technologies (AXNX)

Deals this week: Smartsheet, AT&T, BP, Cleveland-Cliffs, Vistra and more

Axonics gets regulatory nod for fourth-generation rechargeable SNM system in Australia

Axonics gains after Boston Scientific says it will end use of Coaptite on Nov. 1

RBC Capital analyst Shagun Singh Chadha maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report) on October 8 and set a...

Axonics Modulation Technologies (AXNX) Receives a Hold from RBC Capital

Catalyst Watch: Earnings blitz, Fed speakers, and notable healthcare conferences

Axonics' Market Growth Strengthens Boston Scientific's Future

AAPL

ALTM

AMED

ANRO

ANSS

ARMK

ASAN

AXNX

AZNCF

BABA

BABAF

BATL

BIOX

BKNG

BLCO

BOOM

BYON

CACI

CALM

CAMRF

CBOE

CFLT

COST

CPRI

CTLT

DENN

ETON

FFIE

FLUT

GOOG

GOOGL

INFN

JDCMF

JNPR

LBRDA

LBRDB

LBRDK

LBRDP

LOGI

LSXMA

LSXMB

LSXMK

MEDP

MMSI

MNDY

NONOF

OKTA

OMIC

PLTK

PYTCY

QCOM

RIVN

RVNC

SATS

SMAR

SRCL

SRDX

STZHF

TEAM

TMUS

TSLA

UBER

VVPR

WHLR

Press Releases

Axonics Provides Update on Inter Partes Review Proceedings

Axonics Stockholders Approve Merger Agreement with Boston Scientific

Boston Scientific Announces Results for First Quarter 2024

Axonics Reports First Quarter 2024 Financial Results

Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia

Kestra Medical Technologies Announces Appointment of Veteran Medical Device Executive, Raymond W. Cohen, to its Board of Directors

Axonics Reports Second Quarter 2024 Financial Results

Axonics Prevails in Patent Infringement Lawsuit with Medtronic

Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia

Comments

Axonics

空売り

Axonics (NASDAQ:AXNX) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル